Artiva Biotherapeutics, Inc. (ARTV) Price & Analysis

Compare

34 Followers

ARTV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.78 - $17.31

Previous CloseN/A

Volume23.16K

Average Volume (3M)135.19K

Market Cap

$47.75M

Enterprise Value$127.92M

Total Cash (Recent Filing)$185.43M

Total Debt (Recent Filing)$14.35M

Price to Earnings (P/E)―

Beta0.67

Next Earnings

Aug 28, 2025

EPS Estimate

-0.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.83

Shares Outstanding24,363,120

10 Day Avg. Volume126,302

30 Day Avg. Volume135,185

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)-1.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.69

Enterprise Value/Market Cap2.68

Enterprise Value/Revenue15.88

Enterprise Value/Gross Profit509.63

Enterprise Value/Ebitda-0.67

Forecast

1Y Price Target

$17.00

Price Target Upside729.27% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Artiva Biotherapeutics, Inc. News

See All ARTV News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial PositionFinancially, the company is well-positioned, having reported a strong cash position which could fund operations into 2027, encompassing key clinical data milestones.

Product DevelopmentArtiva's primary asset, AB-101, an allogeneic, 'off the shelf,' non-genetically modified natural killer (NK) cell therapy is being evaluated in various B-cell driven autoimmune diseases and has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment.

Regulatory ApprovalIn February 2024, AlloNK received FDA fast track designation for the treatment of lupus nephritis combined with RTX/OBI, which is viewed favorably as it will streamline clinical development and regulatory interactions.

Bears Say

Competitive LandscapeManufacturers flooded the SLE/LN space to replicate Schett's autoimmune reset, creating enrollment changes and generating small datasets across indications that don't live up to the initial bar set by Schett.

Market UncertaintyThe target price is being adjusted to reflect broader market uncertainty.

Regulatory EnvironmentManagement commented that recent changes in CBER are not a positive.

Financials

Income Statement >

ARTV FAQ

What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?

Artiva Biotherapeutics, Inc. lowest stock price was $1.78 and its highest was $17.31 in the past 12 months.

What is Artiva Biotherapeutics, Inc.’s market cap?

Artiva Biotherapeutics, Inc.’s market cap is $47.75M.

When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?

Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Aug 28, 2025 which is in 75 days.

How were Artiva Biotherapeutics, Inc.’s earnings last quarter?

Artiva Biotherapeutics, Inc. released its earnings results on May 08, 2025. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.711 by -$0.119.

Is Artiva Biotherapeutics, Inc. overvalued?

According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Artiva Biotherapeutics, Inc. pay dividends?

Artiva Biotherapeutics, Inc. does not currently pay dividends.

What is Artiva Biotherapeutics, Inc.’s EPS estimate?

Artiva Biotherapeutics, Inc.’s EPS estimate is -0.81.

How many shares outstanding does Artiva Biotherapeutics, Inc. have?

Artiva Biotherapeutics, Inc. has 24,363,120 shares outstanding.

What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?

Artiva Biotherapeutics, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.711. Following the earnings report the stock price went up 3.81%.

Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?

Currently, no hedge funds are holding shares in ARTV

Artiva Biotherapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-68.14%

Trailing 12-Months

Asset Growth

112.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. (ARTV) is a biotechnology company specializing in the development and commercialization of cell therapies for cancer treatment. The company focuses on harnessing the power of natural killer (NK) cells, which are a type of immune cell capable of targeting and destroying cancerous cells. Artiva's core products include a pipeline of allogeneic NK cell therapies designed to address a variety of hematological and solid tumor cancers. The company operates within the biotechnology and healthcare sectors, aiming to improve patient outcomes through innovative immunotherapy solutions.

ARTV Stock 12 Month Forecast

Average Price Target

$17.00

▲(729.27%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Sep<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,3.3292307692307688,4.718461538461538,6.107692307692307,7.496923076923077,8.886153846153846,10.275384615384613,11.664615384615383,13.053846153846152,14.443076923076921,15.83230769230769,17.22153846153846,18.61076923076923,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,3.0984615384615384,4.256923076923076,5.415384615384616,6.573846153846153,7.7323076923076925,8.89076923076923,10.04923076923077,11.207692307692307,12.366153846153844,13.524615384615384,14.683076923076923,15.84153846153846,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,2.713846153846154,3.4876923076923076,4.2615384615384615,5.035384615384615,5.809230769230769,6.5830769230769235,7.356923076923076,8.13076923076923,8.904615384615385,9.678461538461539,10.452307692307691,11.226153846153846,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.77,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.77,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.77,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.77,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.59,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.54,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >